NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis SA (NASDAQ:CLLS) posted its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.51. The biotechnology company had revenue of $10.21 million for the quarter, compared to the consensus estimate of $1.40 million. Cellectis had a negative return on equity of 21.03% and a negative net margin of 446.75%. View Cellectis' Earnings History.

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Cellectis.

6 Wall Street analysts have issued 12 month price targets for Cellectis' stock. Their forecasts range from $20.00 to $73.00. On average, they anticipate Cellectis' stock price to reach $40.40 in the next twelve months. This suggests a possible upside of 124.2% from the stock's current price. View Analyst Price Targets for Cellectis.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

News coverage about CLLS stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectis earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Cellectis.

Cellectis saw a decline in short interest in December. As of December 31st, there was short interest totalling 245,100 shares, a decline of 22.7% from the December 15th total of 316,900 shares. Based on an average daily volume of 121,400 shares, the short-interest ratio is currently 2.0 days. Currently, 0.6% of the company's shares are short sold. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Alector (ALEC), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS) and DBV TECHNOLOGIE/S (DBVT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Alibaba Group (BABA), Editas Medicine (EDIT), WEC Energy Group (WEC) and Neurocrine Biosciences (NBIX).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.34%).

CLLS stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $18.02.

Cellectis has a market capitalization of $764.95 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.View Additional Information About Cellectis.

The official website for Cellectis is http://www.cellectis.com/.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]